Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 3Lymphoid 2Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

Paclitaxel 192Carboplatin 159pembrolizumab 118Bevacizumab 86liposomal doxorubicin 68Gemcitabine 62Cisplatin 55olaparib 49Topotecan 47Nivolumab 32niraparib 30Cyclophosphamide 30Doxorubicin 29Docetaxel 261-dodecylpyridoxal 22Injections 21Drug Therapy 20human papillomavirus vaccine, L1 type 16, 18 19fludarabine 18atezolizumab 18Pemetrexed 18lenvatinib 17mirvetuximab soravtansine 16Fulvestrant 16avelumab 15Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 15durvalumab 14Oxaliplatin 13Irinotecan 13Fluorouracil 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Influenza Vaccines × Gynecologic × Clear all
NCT05069935 2023-09-21

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
16 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡